Osteoporosis in women after menopause is one of the most common and clinically significant bone conditions in women’s health. Approximately one in two women over the age of 50 will sustain a fragility fracture in their remaining lifetime — a fracture resulting from no more force than a fall from standing height. The fundamental driver is oestrogen deficiency at the menopause, which removes a critical brake on osteoclast (bone-resorbing cell) activity and triggers a phase of accelerated bone loss that, in some women, reduces bone mineral density from the normal to the osteoporosis range within a decade. Understanding why this happens, how to identify who is at highest risk, and what can be done about it — from lifestyle changes through hormone replacement to pharmacological treatment — is important for every woman approaching or past the menopause.
Postmenopausal osteoporosis is often called a “silent” condition because bone loss itself causes no symptoms — it is typically a fracture (wrist, vertebra, hip) that reveals the extent of bone loss that has been occurring undetected. Vertebral fractures may occur with minimal trauma (bending to lift a bag, sneezing) and may not even be recognised at the time; they are found incidentally on X-rays taken for other reasons and contribute to the progressive height loss and increasing thoracic kyphosis (“dowager’s hump”) that some postmenopausal women develop. Hip fractures are more dramatic and always come to medical attention, but their consequences — surgery, prolonged immobility, loss of independence, and a 20% one-year mortality — make prevention the only acceptable strategy. Prevention depends on understanding the biology of postmenopausal bone loss and acting on it before the fracture occurs.
Why the Menopause Affects Bone
Throughout reproductive life, oestrogen suppresses osteoclast activity by promoting osteoclast apoptosis (programmed cell death) and inhibiting the production of RANKL — a signalling molecule that activates osteoclast precursors. This means that in premenopausal women, the normal remodelling cycle (osteoclast resorption followed by osteoblast formation) is kept in relative balance by oestrogen’s restraining effect on resorption.
At the menopause, circulating oestrogen levels fall to near-zero within months. The osteoclast-suppressing effect is removed: osteoclasts become more active and more numerous, resorbing bone faster than osteoblasts can replace it. The net result is bone loss. The rate of loss is highest in the first five to ten years after the final menstrual period — typically 2–3% of bone mineral density per year in this acute phase — then slows to approximately 1% per year for the remainder of life. Trabecular (spongy) bone, which predominates in the vertebrae and wrist, is most rapidly depleted in the early postmenopausal years; cortical (compact) bone, which predominates at the hip, is more affected in later decades.
The cumulative effect of this loss pattern means that vertebral fractures tend to occur earlier in postmenopausal life (50s and 60s), while hip fractures become more common in the 70s and 80s when cortical bone loss at the hip adds to the earlier trabecular deficit. Both fracture types cause significant morbidity — vertebral fractures through pain, height loss, and kyphosis; hip fractures through hospitalisation, surgical repair, loss of independence, and a 20% mortality rate within 12 months.
Early and Surgical Menopause
Women who experience menopause before the age of 45 — whether natural, induced by chemotherapy, or surgical (bilateral oophorectomy) — face significantly higher lifetime fracture risk. This is because the period of oestrogen-deficient bone loss begins earlier, accumulates over more years before any screening or treatment intervention, and starts from a peak bone mass that has had less time to consolidate.
Women who have a bilateral oophorectomy (surgical removal of both ovaries) before the natural menopause face the same bone health consequences as early menopause, with the additional consideration that the onset of oestrogen deficiency is abrupt rather than gradual — there is no perimenopausal transition during which partial adaptation can occur.
In both early and surgical menopause, hormone replacement therapy (HRT) is the most important bone-protective intervention. For women under 50 with early menopause, NICE guidance specifically recommends HRT until at least the age of natural menopause (typically 51–52) because the benefits — which include bone protection, cardiovascular protection in this age group, and relief of menopausal symptoms — outweigh the risks substantially. For women under 45 with surgical menopause who do not take HRT, DEXA bone density assessment and consideration of pharmacological bone protection is appropriate from the time of surgery.
Who Is at Highest Risk?
Within the postmenopausal population, fracture risk is not uniform. Several factors increase the risk above the baseline postmenopausal level:
- Early menopause (before 45) — longer oestrogen-deficient bone loss period
- Family history of hip fracture in a parent — approximately doubles fracture risk
- Prior fragility fracture — strongest single predictor of next fracture
- Low body weight (BMI below 19) — less mechanical loading and less adipose-derived oestrogen
- Smoking — impairs osteoblast function; independently associated with earlier menopause
- Glucocorticoid use — any woman on long-term steroids should have bone protection co-prescribed
- Long-term glucocorticoid treatment for inflammatory conditions (rheumatoid arthritis, inflammatory bowel disease) is a particularly important compounding risk
- Low calcium and vitamin D intake — inadequate nutritional support for bone mineralisation
- Physical inactivity — loss of weight-bearing stimulus on bone formation
The FRAX tool combines all of these factors with or without a bone mineral density (BMD) result from a DEXA scan to produce a 10-year fracture probability estimate that guides whether treatment is appropriate. Detail on FRAX and DEXA is in our guides to osteoporosis risk factors and DEXA scan: what adults should know.
The Perimenopause and Bone Health
The perimenopausal transition — the two to four years before the final menstrual period, during which oestrogen secretion becomes irregular and then falls — is itself a period of early bone loss. Studies using high-resolution imaging and bone turnover markers (blood and urine tests that measure the rate of bone resorption and formation) show that the upswing in bone resorption begins in the late perimenopause, often one to two years before the final menstrual period and while cycles are still irregular.
This means that a woman who does not begin losing bone at the exact moment of the final period — she may already have lost a small but measurable proportion of her bone density during the perimenopause. For most women this is not clinically significant in isolation, but for women with borderline T-scores or additional risk factors, it represents a further increment of bone loss on top of an already adverse starting position.
Bone turnover markers — specifically serum CTX (C-telopeptide of type I collagen, a resorption marker) and serum P1NP (N-terminal propeptide of type I procollagen, a formation marker) — are sometimes used by specialists to assess the rate of postmenopausal bone loss and to monitor treatment response without waiting for a repeat DEXA. A rapidly rising CTX in early menopause, with P1NP not keeping pace, indicates net bone resorption and may prompt earlier intervention in women with borderline FRAX or T-score results. CTX also provides a useful monitoring marker during bisphosphonate treatment: a fall of 50–75% from pretreatment baseline at three months indicates that the medication is suppressing osteoclast activity as expected.
The perimenopausal and early postmenopausal period is also when HRT has its greatest bone-protecting benefit. Starting HRT in the early menopause, when bone loss rates are highest and the anti-resorptive effect of oestrogen restoration is most potent, is more effective at preserving bone density than starting later — adding another reason why timely access to HRT assessment and prescription matters for women approaching menopause with bone health concerns.
Secondary Causes of Osteoporosis in Postmenopausal Women
While postmenopausal oestrogen deficiency is the dominant driver of bone loss in most postmenopausal women, secondary causes are present in a significant proportion of women presenting with osteoporosis or an unexpectedly low T-score. A secondary cause is a medical condition or medication that independently reduces bone density above and beyond the postmenopausal baseline.
Commonly identified secondary causes in postmenopausal women include:
- Coeliac disease — malabsorption of calcium and vitamin D from the small intestine; often under-diagnosed in women, who present more commonly with atypical features (fatigue, anaemia) than the classical gastrointestinal picture
- Primary hyperparathyroidism — autonomous PTH secretion drives cortical bone resorption; may be discovered incidentally on calcium blood testing; affects postmenopausal women disproportionately
- Subclinical hyperthyroidism — including excess levothyroxine dosing in women treated for hypothyroidism; TSH should be maintained within the reference range in women with osteoporosis or significant fracture risk
- Inflammatory bowel disease — both direct effects of chronic inflammation on osteoclast activation and indirect effects of corticosteroid treatment for flares
- Premature ovarian insufficiency — when occurring before the age of 40, and even 40–45 if untreated with HRT, the longer window of low oestrogen is a significant secondary contributor to bone loss beyond the normal postmenopausal trajectory
- Aromatase inhibitors — used for hormone-receptor-positive breast cancer treatment in postmenopausal women; suppress the residual oestrogen production from peripheral aromatisation of adrenal androgens, which is the main oestrogen source in postmenopausal women; associated with bone density loss of 2–3% per year and increased fracture risk — bone protection should be considered from the start of treatment
When a postmenopausal woman has a DEXA T-score lower than expected for her age, or has sustained a fracture without a compelling combination of conventional risk factors, investigation for secondary causes is appropriate. Standard investigations include serum calcium, phosphate, PTH, TSH, vitamin D, coeliac screen (anti-tissue transglutaminase IgA plus total IgA), and renal and liver function. Additional investigations may be directed by clinical context.
Screening Recommendations
NICE guidance recommends assessing fracture risk (using FRAX) in all women aged 65 and over, and in women aged 50–64 with one or more clinical risk factors. DEXA bone density testing is recommended for those whose FRAX score indicates fracture probability above the assessment threshold, or for those with conditions that directly warrant bone density assessment (prior fragility fracture, long-term glucocorticoid use, early menopause).
In practice, this means that many postmenopausal women with significant risk factors are not referred for DEXA at the appropriate time — the fracture that triggers assessment is often the first sign of osteoporosis. Proactively discussing bone health with a GP at the time of menopause, particularly for women with early menopause or additional risk factors, is appropriate and worthwhile.
Prevention and Treatment
Hormone replacement therapy (HRT) is highly effective at preventing postmenopausal bone loss. Oestrogen-containing HRT suppresses the oestrogen-deficient osteoclast activation that drives postmenopausal bone loss, maintaining BMD at premenopausal levels for as long as it is taken. Fracture reduction benefit is well-established. HRT is appropriate for women under 60 who have menopausal symptoms and osteoporosis risk; in these women, the bone protection benefit is additional to symptom relief. For women over 60 who have no menopausal symptoms and are seeking bone protection alone, bisphosphonates are generally preferred. Current NICE guidance (2023) takes a more favourable view of HRT than previous guidance — the risk-benefit balance in women under 60 with symptoms is considered clearly positive for most women.
Bisphosphonates (first-line pharmacological treatment) inhibit osteoclast activity, reduce bone resorption, and significantly reduce fracture risk. Alendronate 70 mg weekly is NICE’s recommended first-choice agent, reducing vertebral fracture risk by approximately 50% and hip fracture risk by approximately 40% over three years. Full detail on pharmacological treatments is in our guide to osteoporosis: symptoms, causes, and prevention.
Calcium and vitamin D: ensuring adequate calcium intake (700–1,200 mg/day from diet and/or supplements) and vitamin D status (supplementation 400–800 IU/day) is the nutritional foundation of bone protection at any stage of postmenopausal life. These are co-prescribed with all pharmacological treatments. More on calcium sources is in our guide to calcium and bone health; vitamin D guidance is in our guide to vitamin D and bone health.
Exercise: weight-bearing aerobic exercise and resistance training maintain bone density, improve balance, and reduce falls risk. Both are recommended for all postmenopausal women regardless of bone density status. The combination of higher-impact weight-bearing activity (brisk walking, tennis, aerobics) and twice-weekly resistance training is the most evidence-supported exercise programme for postmenopausal bone health.
Frequently Asked Questions
How much bone do women lose after menopause?
In the acute phase of menopause — approximately the first five to ten years after the final menstrual period — women lose bone mineral density at a rate of approximately 2–3% per year. Over a ten-year acute phase, this represents a potential total loss of 20–30% of the BMD present at menopause. After this acute phase, loss slows to approximately 1% per year. The cumulative impact is substantial: a woman who reaches menopause with T-scores at the lower end of normal (−0.8 to −1.0) at age 51, losing 2.5% per year for ten years, could reasonably reach the osteoporosis threshold (T-score −2.5) by her early sixties without any other risk factors. This is the biological basis for DEXA screening recommendations in postmenopausal women.
Does HRT protect against osteoporosis?
Yes — oestrogen-containing HRT effectively prevents postmenopausal bone loss and significantly reduces fracture risk for as long as it is taken. The benefit is dose-dependent and is maintained throughout the period of HRT use. However, the bone-protective benefit is lost after HRT is stopped — bone loss resumes at the postmenopausal rate within a year of discontinuation. This means that HRT provides ongoing protection during use, but does not provide lasting skeletal benefit after stopping in the way that bisphosphonates (which remain in bone mineral for years) do. For women who take HRT for menopausal symptoms and then stop in their early to mid 60s, DEXA assessment at that point is appropriate to determine whether a bisphosphonate should be started to maintain the bone density preserved during HRT use.
Is osteoporosis inevitable after menopause?
No. While all postmenopausal women experience bone loss, whether that loss progresses to osteoporosis (T-score below −2.5) depends on the height of peak bone mass, the rate of loss, the duration of oestrogen deficiency, and the presence of additional risk factors. Women who reach menopause with high peak bone mass (from childhood exercise, adequate calcium and vitamin D during growth, and genetic factors), have natural menopause in their early 50s, maintain weight-bearing exercise, do not smoke, have adequate calcium and vitamin D intake, and have no secondary causes of bone loss may never reach the osteoporosis threshold despite decades of postmenopausal bone loss. Osteoporosis is a risk — a risk that can be managed — not an inevitable consequence of ageing and female sex.
What is the link between early menopause and osteoporosis?
Women who experience menopause before age 45 — whether naturally, from chemotherapy-induced ovarian failure, or from surgical oophorectomy — have a significantly higher lifetime fracture risk than women with natural menopause in the early 50s. This is because the period of oestrogen-deficient bone loss begins earlier, accumulates for more years, and starts from a point earlier in the bone density lifecycle. NICE specifically recommends HRT for women with premature ovarian insufficiency (menopause before 40) and early menopause (40–45) until at least the age of natural menopause — the bone (and cardiovascular) benefits of replacing oestrogen in this age group outweigh the risks associated with HRT in older women.
Can exercise prevent postmenopausal osteoporosis?
Exercise cannot fully counteract the oestrogen-deficient bone loss of the menopause, but it substantially moderates the rate of loss and reduces fracture risk through two mechanisms: maintaining bone mineral density (particularly with resistance training) and reducing fall risk (through muscle strength and balance). Studies of progressive resistance training in early postmenopausal women show BMD improvements at the hip and spine of 1–3% over one to two years — a modest but meaningful effect. Weight-bearing aerobic exercise (brisk walking, jogging, dancing, tennis) provides the mechanical loading stimulus for osteoblast activity. The combination of resistance and weight-bearing activity is more effective than either alone, and both should be maintained consistently throughout postmenopausal life rather than started late in response to a diagnosis.
Should all postmenopausal women take calcium supplements?
Not necessarily, but all postmenopausal women should ensure adequate calcium intake — whether from diet or supplementation. The target is 700–1,200 mg of calcium per day, with dietary sources preferred over supplements where achievable. Women who have adequate dairy or plant calcium in their diet do not need supplemental calcium. Those whose dietary intake is consistently below 700 mg/day benefit from supplemental calcium — ideally as calcium carbonate or citrate, combined with vitamin D for absorption. High-dose calcium supplements (above 1,200 mg/day total from all sources) should be avoided; some data suggest cardiovascular concerns at very high supplemental doses. The priority is ensuring adequacy, not supplementing maximally.
When should postmenopausal women start bisphosphonate treatment?
Bisphosphonate treatment is indicated when fracture risk is high enough — assessed using FRAX and DEXA — that the benefit of treatment (reduced fracture probability) outweighs the risks and side effects. For most women this is when FRAX indicates a 10-year major fracture probability above the NICE intervention threshold (which varies by age), or when the T-score is at or below −2.5, or when a fragility fracture has already occurred. Starting bisphosphonate treatment in all postmenopausal women with osteopenia (T-score between −1.0 and −2.5) is not recommended — many of these women have low enough absolute fracture risk that the benefit does not justify the medication. Treatment decisions are based on FRAX probability, not T-score category alone.
Summary
Osteoporosis in women after menopause is driven by oestrogen deficiency — the loss of oestrogen’s suppression of osteoclast activity triggers a decade of accelerated bone loss that can move T-scores from normal into the osteoporosis range. Early and surgical menopause extend this window and markedly increase lifetime fracture risk. Prevention and treatment combine lifestyle measures (weight-bearing and resistance exercise, calcium and vitamin D adequacy, smoking cessation) with hormone replacement therapy for eligible women, and bisphosphonates or other pharmacological agents when fracture risk is above the treatment threshold. DEXA screening at the right time — before a fracture occurs — gives women and clinicians the information needed to act. Related guides on bone health are available on osteoporosis: symptoms, causes, and prevention, osteopenia, and bone density test: a simple guide.
Medical disclaimer: This article is for general educational purposes and does not constitute medical advice. Consult a qualified healthcare professional for personalised bone health and menopause management advice.
References:
NHS. Osteoporosis. nhs.uk. 2023.
NICE CG146. Osteoporosis: assessing the risk of fragility fracture. NICE. 2023.
NICE NG23. Menopause: diagnosis and management. NICE. 2015 (updated 2024).
Royal Osteoporosis Society. Osteoporosis and the menopause. theros.org.uk. 2023.
Eastell R, et al. Postmenopausal osteoporosis. Nat Rev Dis Primers. 2016;2:16069.
I had a bilateral oophorectomy at 43 for endometriosis and was not given HRT at that time — my surgeon mentioned it as an option but did not strongly recommend it and I was worried about the breast cancer risk I’d heard about. It wasn’t until I had a vertebral fracture at 52 — bending to lift a box — that anyone connected my early surgical menopause to my bone health. My GP referred me to a fracture liaison service, who organised a DEXA and FRAX assessment. My T-score was −2.8 at the spine and −2.4 at the hip. My FRAX 10-year major fracture probability was 28%, which they said was very high for my age. They started me on alendronate and calcium and vitamin D and referred me to a specialist for a conversation about HRT. I wish I had known at 43 what this article explains: that surgical menopause at that age has significant bone consequences, and that HRT to natural menopause age is specifically recommended for exactly this reason.
Diana, your case reflects a pattern seen too commonly: surgical menopause at 43 without proactive bone protection, and a fracture in the early 50s that reveals accumulated postmenopausal bone loss spanning nearly a decade. From age 43 to 52, your oestrogen-deficient bone loss — in the absence of HRT — would have followed the acute postmenopausal trajectory of 2–3% per year: potentially 18–27% of spinal BMD over nine years before treatment began. Your T-score of −2.8 at 52 is consistent with this degree of cumulative loss from a starting point that was likely in the normal or osteopenia range before oophorectomy. Starting HRT at the time of surgery would have maintained your BMD through to natural menopause age and substantially reduced your fracture risk. Current NICE guidance now makes this recommendation explicit, but it continues to require proactive discussion with patients at the time of surgery. Fiona, your management is well-structured. The planned DEXA 18 months after stopping HRT is exactly the appropriate surveillance strategy — it captures the rate of bone loss in the immediate post-HRT period, which is when loss is most rapid (resuming the acute postmenopausal trajectory), and allows a timely decision about whether bisphosphonate initiation is appropriate to protect the BMD accumulated during your decade of HRT use.
I’m 59, went through natural menopause at 50, and have been on HRT (oestradiol patch plus progesterone) since 51 for vasomotor symptoms. I’ve had two DEXA scans — at 53 and at 58. My T-score at the spine was −0.6 at the first scan and −0.8 at the second — so a small decrease over five years on HRT but still comfortably in the normal range. My GP has said that when I come off HRT (I’m planning to do so at 60 or 61) I should have another DEXA about 18 months after stopping to see whether the rate of bone loss increases significantly at that point. The explanation in this article about bone loss resuming at the postmenopausal rate after stopping HRT, and the suggestion of DEXA assessment when stopping in the 60s, is exactly what my GP told me. It’s reassuring to see that reflected in clear public information.